Last reviewed · How we verify
Bacillus coagulans
At a glance
| Generic name | Bacillus coagulans |
|---|---|
| Sponsor | Xijing Hospital of Digestive Diseases |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Synbiotic Supplement With Botanical Extracts for Gut Microbiota Balance in Irritable Bowel Syndrome (NA)
- Impact of Supplementation With Synbiotics and Prebiotics on Cognitive Decline Associated With Neoadjuvant Chemotherapy in First-line Patients With Breast Cancer (NA)
- Assessing Role of Probiotics in Children Aged 6-36 Months Treated for Pneumonia (NA)
- Impact of Weizmannia (Bacillus) Coagulans JBI-YZ6.3 on Gut Health and Fecal Microbiome Changes (NA)
- To Evaluate the Effect of Bacillus Coagulans Based Product in Gut Health and Immunomodulatory Effect in Healthy Adults (NA)
- Effects of Bacillus Coagulans SNZ 1969 on Immune Health in Healthy School-aged Children (NA)
- Weizmannia Coagulans BC99 Relieves Exercise-induced Fatigue (NA)
- Sports Nutrition Benefits of Weizmannia Coagulans BC99 (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bacillus coagulans CI brief — competitive landscape report
- Bacillus coagulans updates RSS · CI watch RSS
- Xijing Hospital of Digestive Diseases portfolio CI